Zacks Research Has Negative Outlook for MMSI Q4 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Stock analysts at Zacks Research decreased their Q4 2025 earnings estimates for shares of Merit Medical Systems in a research report issued to clients and investors on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $0.85 per share for the quarter, down from their previous estimate of $1.02. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems' Q1 2026 earnings at $0.80 EPS, Q3 2026 earnings at $0.98 EPS and Q4 2026 earnings at $1.02 EPS.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.11. The business had revenue of $355.35 million during the quarter, compared to analyst estimates of $352.57 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The business's revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.77 earnings per share.

Several other analysts have also recently weighed in on MMSI. Canaccord Genuity Group increased their price target on shares of Merit Medical Systems from $108.00 to $112.00 and gave the company a "buy" rating in a research note on Wednesday. JPMorgan Chase & Co. started coverage on Merit Medical Systems in a report on Friday, March 28th. They issued an "overweight" rating and a $120.00 price objective on the stock. Needham & Company LLC raised their target price on Merit Medical Systems from $100.00 to $108.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Raymond James reduced their target price on Merit Medical Systems from $116.00 to $108.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Finally, Wells Fargo & Company increased their price target on Merit Medical Systems from $106.00 to $108.00 and gave the stock an "overweight" rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $109.33.

Merit Medical Systems Trading Down 1.4%

Shares of MMSI traded down $1.38 during mid-day trading on Monday, reaching $95.11. The stock had a trading volume of 542,556 shares, compared to its average volume of 518,498. Merit Medical Systems has a 52-week low of $80.02 and a 52-week high of $111.45. The firm has a market cap of $5.62 billion, a price-to-earnings ratio of 46.62, a P/E/G ratio of 2.34 and a beta of 0.70. The business's fifty day moving average is $96.72 and its 200 day moving average is $100.56. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82.

Institutional Investors Weigh In On Merit Medical Systems

A number of hedge funds have recently added to or reduced their stakes in MMSI. Opal Wealth Advisors LLC purchased a new stake in shares of Merit Medical Systems during the first quarter worth $31,000. NewSquare Capital LLC acquired a new position in Merit Medical Systems during the 4th quarter worth $32,000. IFP Advisors Inc increased its holdings in Merit Medical Systems by 1,435.0% during the 1st quarter. IFP Advisors Inc now owns 307 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 287 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in Merit Medical Systems by 119.8% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 367 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 200 shares in the last quarter. Finally, Bayforest Capital Ltd purchased a new position in shares of Merit Medical Systems in the 1st quarter valued at about $41,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director F. Ann Millner sold 21,250 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $96.47, for a total transaction of $2,049,987.50. Following the transaction, the director now owns 34,543 shares of the company's stock, valued at approximately $3,332,363.21. This represents a 38.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen C. Evans sold 5,000 shares of Merit Medical Systems stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $105.31, for a total value of $526,550.00. Following the completion of the transaction, the director now directly owns 4,657 shares of the company's stock, valued at approximately $490,428.67. This represents a 51.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 130,382 shares of company stock worth $13,189,508 over the last ninety days. Corporate insiders own 3.20% of the company's stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.